WHO ICTRP trial
Study to determine the dose and safety of asciminib in pediatric patients with…
JPRN-jRCT2031210591 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031210591 |
|---|---|
| Public title | Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia |
| Scientific title | A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors - ASC4Kids |
| Primary sponsor | Yamauchi Kyosuke |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 1-2 |
| Countries | France;Japan;Germany;Japan;Hungary;Japan;Italy;Japan;Greece;Japan;Nertherlands;Japan;Poland;Japan;Russia;Japan;Korea;Japan;Thailand;Japan;Turkey;Japan;China;Japan;US;Japan |
| Conditions | Philadelphia chromosome positive chronic myeloid leukemia in chronic phase |
| Interventions | Drug: Asciminib Pediatric formulation group Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally: 10 mg (10x 1 mg tablets in capsule) BID 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in… |
| Registration date | Jan 2, 2022 |
| Target size | 3 |
| Secondary IDs | NCT04925479 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: